These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 15162150)

  • 1. An evaluation of liquid-based cytology and human papillomavirus testing within the UK cervical cancer screening programme.
    Sherlaw-Johnson C; Philips Z
    Br J Cancer; 2004 Jul; 91(1):84-91. PubMed ID: 15162150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy.
    Kim JJ; Wright TC; Goldie SJ
    J Natl Cancer Inst; 2005 Jun; 97(12):888-95. PubMed ID: 15956650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening.
    Kitchener HC; Almonte M; Gilham C; Dowie R; Stoykova B; Sargent A; Roberts C; Desai M; Peto J;
    Health Technol Assess; 2009 Nov; 13(51):1-150, iii-iv. PubMed ID: 19891902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing.
    van Rosmalen J; de Kok IM; van Ballegooijen M
    BJOG; 2012 May; 119(6):699-709. PubMed ID: 22251259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lifetime effects, costs, and cost effectiveness of testing for human papillomavirus to manage low grade cytological abnormalities: results of the NHS pilot studies.
    Legood R; Gray A; Wolstenholme J; Moss S
    BMJ; 2006 Jan; 332(7533):79-85. PubMed ID: 16399769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Projected Impact of HPV and LBC Primary Testing on Rates of Referral for Colposcopy in a Canadian Cervical Cancer Screening Program.
    Coldman AJ; Phillips N; van Niekerk D; Smith L; Krajden M; Cook D; Quinlan DJ; Ehlen T; Miller D; Stuart GC; Peacock S; Martin RE; Franco EL; Ogilvie G
    J Obstet Gynaecol Can; 2015 May; 37(5):412-420. PubMed ID: 26168101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The development of a quality assurance programme for HPV testing within the UK NHS cervical screening LBC/HPV studies.
    Cubie HA; Moore C; Waller M; Moss S;
    J Clin Virol; 2005 Aug; 33(4):287-92. PubMed ID: 16036178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis.
    Karnon J; Peters J; Platt J; Chilcott J; McGoogan E; Brewer N
    Health Technol Assess; 2004 May; 8(20):iii, 1-78. PubMed ID: 15147611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination.
    Goldhaber-Fiebert JD; Stout NK; Salomon JA; Kuntz KM; Goldie SJ
    J Natl Cancer Inst; 2008 Mar; 100(5):308-20. PubMed ID: 18314477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HPV for cervical cancer screening (HPV FOCAL): Complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer.
    Ogilvie GS; Krajden M; van Niekerk D; Smith LW; Cook D; Ceballos K; Lee M; Gentile L; Gondara L; Elwood-Martin R; Peacock S; Stuart G; Franco EL; Coldman AJ
    Int J Cancer; 2017 Jan; 140(2):440-448. PubMed ID: 27685757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The health and economic effects of HPV DNA screening in The Netherlands.
    Berkhof J; Coupé VM; Bogaards JA; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ
    Int J Cancer; 2010 Nov; 127(9):2147-58. PubMed ID: 20112339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus.
    Goldie SJ; Freedberg KA; Weinstein MC; Wright TC; Kuntz KM
    Am J Med; 2001 Aug; 111(2):140-9. PubMed ID: 11498068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of human papillomavirus screening for cervical cancer. A review of recent modelling studies.
    Holmes J; Hemmett L; Garfield S
    Eur J Health Econ; 2005 Mar; 6(1):30-7. PubMed ID: 15682286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinician's view: role of human papillomavirus testing in the American Society for Colposcopy and Cervical Pathology Guidelines for the management of abnormal cervical cytology and cervical cancer precursors.
    Cox JT;
    Arch Pathol Lab Med; 2003 Aug; 127(8):950-8. PubMed ID: 12952506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.
    Kim JJ; Burger EA; Sy S; Campos NG
    J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27754955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cervical cancer screening program based on primary DNA-HPV testing in a Brazilian city: a cost-effectiveness study protocol.
    Teixeira JC; Vale DB; Bragança JF; Campos CS; Discacciati MG; Zeferino LC
    BMC Public Health; 2020 Apr; 20(1):576. PubMed ID: 32345284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.
    Cuzick J; Arbyn M; Sankaranarayanan R; Tsu V; Ronco G; Mayrand MH; Dillner J; Meijer CJ
    Vaccine; 2008 Aug; 26 Suppl 10():K29-41. PubMed ID: 18847555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost and logistics of alternative roll-out options for implementing human papillomavirus testing as a triage in cervical screening: results of the sentinel sites study.
    Legood R; Sadique Z; Patnick J; Kitchener H; Kelly R; Moss S
    Br J Cancer; 2012 Oct; 107(9):1574-9. PubMed ID: 23037717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementation of HPV-based cervical cancer screening in an organised regional screening programme: 3 years of experience.
    Veijalainen O; Kares S; Kujala P; Vuento R; Osuala V; Tirkkonen M; Luukkaala T; Kholová I; Mäenpää J
    Cytopathology; 2019 Mar; 30(2):150-156. PubMed ID: 30421573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MAVARIC - a comparison of automation-assisted and manual cervical screening: a randomised controlled trial.
    Kitchener HC; Blanks R; Cubie H; Desai M; Dunn G; Legood R; Gray A; Sadique Z; Moss S;
    Health Technol Assess; 2011 Jan; 15(3):iii-iv, ix-xi, 1-170. PubMed ID: 21266159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.